DXCM — DexCom, Inc. Stock Price, Chart & AI Report

Positive Feb 25, 2026 • 14:15 UTC The Motley Fool • Prosper Junior Bakiny

Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars

DexCom is positioned as an under-the-radar beneficiary of the GLP-1 medication boom. Rather than being harmed by GLP-1 drugs, DexCom's continuous glucose monitoring devices are increasingly prescribed alongside GLP-1 medications, with studies showing better patient outcomes when used together. The company has a massive addressable market with over 9 million U.S. patients eligible for reimbursement but not yet using CGM devices, compared to its current 2.5 million global installed base.

DXCM GLP-1 medications continuous glucose monitoring (CGM) medical devices diabetes treatment market expansion reimbursement healthcare stocks

Sentiment note

DexCom is presented as a compelling investment opportunity due to its complementary relationship with GLP-1 drugs rather than competitive displacement, significant underpenetrated addressable market with 9 million eligible U.S. patients, strong gross margins (60.44%), and multiple growth tailwinds beyond GLP-1 adoption including market expansion and reimbursement efforts.

Positive Feb 13, 2026 • 18:48 UTC Benzinga • Piero Cingari

Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday?

Wall Street rebounded Friday after softer-than-expected inflation data reinforced expectations for interest-rate cuts. Annual inflation slowed to 2.4% in January, the lowest since May 2025, while core inflation eased to 2.5%. Small caps led gains with the Russell 2000 climbing 1.8%. Commodities surged with gold up 2%, silver up 4%, and Bitcoin rallying 4.6%. Strong earnings from tech and other sectors drove individual stock gains, with Rivian jumping 27% and Coinbase surging 17%.

IWM RIVN COIN AMAT inflation interest-rate cuts small caps Russell 2000

Sentiment note

Gained 9% on positive earnings performance

Negative Dec 26, 2025 • 21:56 UTC GlobeNewswire Inc. • Levi & Korsinsky, Llp

DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM

DexCom faces a class action securities lawsuit alleging the company made unauthorized design changes to its G6 and G7 glucose monitoring devices without FDA approval, rendering them less reliable and presenting health risks to users. The complaint claims defendants overstated the devices' enhancements and concealed the true scope of issues, exposing the company to regulatory scrutiny and significant financial harm. Investors who suffered losses between January 8, 2024 and September 17, 2025 can join the lawsuit.

DXCM securities fraud class action lawsuit glucose monitoring devices FDA violations product reliability investor losses

Sentiment note

The company faces serious allegations of securities fraud, unauthorized product design changes, FDA violations, and concealment of health risks associated with its medical devices. These factors pose significant legal, regulatory, and reputational risks that negatively impact investor confidence and shareholder value.

Negative Dec 26, 2025 • 19:18 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm

A class action lawsuit has been filed against DexCom, Inc. for allegedly making materially false and misleading statements regarding unauthorized FDA design changes to its G6 and G7 glucose monitoring devices. The lawsuit claims these changes reduced device reliability and accuracy, posing health risks to users, while the company overstated the devices' enhancements. Investors who purchased DexCom securities between July 26, 2024 and September 17, 2025 have until December 26, 2025 to apply as lead plaintiff.

DXCM class action lawsuit FDA violations unauthorized design changes device reliability glucose monitoring securities fraud investor losses

Sentiment note

The company faces serious allegations of making unauthorized FDA design changes to critical medical devices, misrepresenting device reliability and accuracy, and exposing users to health risks. These violations expose DexCom to regulatory enforcement, legal liability, reputational damage, and financial harm, making this highly negative for investors and stakeholders.

Negative Dec 26, 2025 • 14:00 UTC GlobeNewswire Inc. • The Schall Law Firm

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors to join a class action lawsuit against DexCom, Inc. for securities fraud. The complaint alleges that DexCom made unauthorized changes to its G6 and G7 glucose monitoring systems without FDA approval, resulting in reduced reliability and health risks to users. The company allegedly downplayed the severity of these risks in public statements during the class period from July 26, 2024 to September 17, 2025.

DXCM securities fraud class action lawsuit DexCom FDA authorization product reliability shareholder litigation G6 and G7 systems

Sentiment note

The company is accused of making false and misleading statements, making unauthorized product changes without FDA approval, reducing product reliability, and downplaying health risks to consumers. These allegations of fraud and regulatory violations represent significant legal and reputational risks.

Negative Dec 23, 2025 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against DexCom, Inc. alleging that the company made unauthorized material design changes to its G6 and G7 glucose monitoring devices without FDA approval, rendering them less reliable and presenting health risks to users. The lawsuit covers investors who purchased DexCom securities between January 8, 2024 and September 17, 2025. The lead plaintiff deadline is December 26, 2025.

DXCM class action lawsuit securities fraud DexCom G6 and G7 devices FDA violations unauthorized design changes investor losses

Sentiment note

The company faces a class action lawsuit alleging material misstatements regarding unauthorized FDA design changes to its glucose monitoring devices, reduced device reliability, health risks to users, and overstated product enhancements. These allegations expose DexCom to regulatory enforcement action, legal liability, reputational damage, and financial harm.

Negative Dec 23, 2025 • 00:29 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm

A class action lawsuit has been filed against DexCom, Inc. alleging the company made unauthorized material design changes to its G6 and G7 glucose monitoring devices without FDA approval, rendering them less reliable and presenting health risks to users. The complaint claims DexCom made false statements about device enhancements and downplayed the severity of issues, exposing the company to regulatory scrutiny and financial harm. Investors who purchased DexCom securities between July 26, 2024 and September 17, 2025 have until December 26, 2025 to apply as lead plaintiff.

DXCM class action lawsuit FDA violations unauthorized design changes glucose monitoring devices securities fraud product reliability regulatory enforcement

Sentiment note

The company faces serious allegations of making unauthorized FDA design changes to critical medical devices, misrepresenting product reliability and safety, and exposing users to health risks. These violations expose DexCom to significant regulatory, legal, reputational, and financial consequences.

Negative Dec 16, 2025 • 23:30 UTC GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

DexCom, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

A securities class action lawsuit has been filed against DexCom alleging unauthorized design changes to glucose monitoring systems, potential health risks, and misleading statements about device reliability during the period of January 8, 2024 to September 17, 2025.

DXCM securities fraud class action glucose monitoring FDA device reliability

Sentiment note

Lawsuit alleges multiple serious issues including unauthorized device design changes, potential health risks, overstated device enhancements, and misleading public statements about product reliability and functionality

Negative Dec 16, 2025 • 20:45 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DexCom and CarMax and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire announced class action lawsuits against DexCom and CarMax, alleging false statements about business operations and misleading investors during specific time periods.

DXCM KMX class action lawsuit securities investor rights

Sentiment note

Lawsuit alleges unauthorized FDA design changes to medical devices, reduced reliability, health risks, and potential regulatory scrutiny that could harm company reputation and financial standing

Negative Dec 16, 2025 • 18:50 UTC GlobeNewswire Inc. • Rosen Law Firm

DXCM DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important December 29 Deadline in Securities Class Action – DXCM

Rosen Law Firm alerts DexCom investors about a securities class action lawsuit alleging unauthorized design changes to glucose monitoring systems that potentially compromised device reliability and user health risks.

DXCM securities class action glucose monitoring FDA investor rights

Sentiment note

The lawsuit alleges multiple serious issues including unauthorized device design changes, compromised device reliability, potential health risks, and potential regulatory and reputational harm to the company

Negative Dec 16, 2025 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against DexCom alleging unauthorized design changes to G6 and G7 glucose monitoring devices that potentially compromise device reliability and user health safety.

DXCM KMX securities fraud class action medical device FDA investor lawsuit

Sentiment note

Lawsuit alleges material design changes unauthorized by FDA, device reliability issues, potential health risks, and potential regulatory and reputational damage

Negative Dec 16, 2025 • 14:00 UTC GlobeNewswire Inc. • Lesley F. Portnoy

Portnoy Law Firm Announces Class Action on Behalf of DexCom, Inc. Investors

The Portnoy Law Firm announced a class action lawsuit against DexCom for allegedly making false statements about design changes and reliability of their G6 and G7glucose monitoring devices, which may pose health risks and regulatory challenges.

DXCM class action lawsuit medical devices FDA glucose monitoring

Sentiment note

The lawsuit alleges material design changes to medical devices without FDA authorization, potential health risks, overstated device reliability, and potential regulatory and reputational harm